IP Library Granted Patent US 7,901,893
Granted Patent B2
US 7,901,893 · App. 10/586,310 · Granted Mar 8, 2011

NPC1L1 (NPC3) and methods of identifying ligands thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,901,893
App. No.
10/586,310
Granted
Mar 8, 2011
Kind
B2
Abstract

The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject.

Claims (18)

1. A method for identifying a ligand of NPC1L1 comprising:

(a) contacting human NPC1L1 with a candidate compound and a detectably labeled substituted 2-azetidinone glucuronide compound selected from the group consisting of compound 1, compound 8

and a compound of Formula II a

wherein,

R 9 is selected from the group consisting of —C≡C—CH 2 —NR 10 R 11 wherein R 11 is selected from the group consisting of —H, —C 1-3 alkyl, —C(O)—C 1-3 alkyl, —C(O)—NR 10 R 10 , —SO 2 —C 1-3 alkyl and —SO 2 -phenyl; —C≡C(O)NR 10 —SO 2 —C 1-3 alkyl; —C≡C—C(O)NR 10 —SO 2 —phenyl; —(CH 2 ) 3 —NR 10 —SO 2 -phenyl;

R 10 is independently selected at each occurrence from —H and —C 1-3 alkyl; and

R 12 is selected from

(b) measuring the amount of detectably labeled substituted 2-azetidinone glucuronide compound that is bound to NPC1L1,

wherein binding of said candidate compound to human NPC1L1 decreases binding of said detectably labeled substituted 2-azetidinone glucuronide to human NPC1L1, and indicates that the candidate compound is a ligand of human NPC1L1.

2. The method of claim 1 , wherein the substituted 2-azetidinone-glucuronide comprises a detectable label from the group consisting of 3 H, 35 S and 125 I.

3. The method of claim 2 , wherein the substituted 2-azetidinone-glucuronide is a compound of Formula IIa.

4. The method of claim 3 , wherein the substituted 2-azetidinone-glucuronide is a compound of Formula IIa, wherein R 9 is selected from the group consisting of —C≡C—CH 2 —NR 10 R 11 , —C≡C—C(O)NR 10 R 11 , —(CH 2 ) 3 —NR 10 —SO 2 —C 1-3 alkyl and —(CH 2 ) 3 —NR 10 —SO 2 -phenyl, and R 11 is selected from —SO 2 —C 1-3 alkyl and —SO 2 -phenyl.

5. The method of claim 4 , wherein the substituted 2-azetidinone-glucuronide of Formula IIa is labeled with 35 S.

6. The method of claim 5 wherein R 9 is —C≡C—CH 2 —NR 10 R 11 .

7. The method of claim 1 wherein the detectably labeled substituted 2-azetidinone glucuronide is 35 S-labeled compound 2

8. The method of claim 1 wherein R 12 is

9. The method of claim 1 wherein the detectably labeled substituted 2-azetidinone glucuronide is selected from the group consisting of compound 1, and compound 8.

10. The method of claim 9 wherein the detectably labeled substituted 2-azetidinone glucuronide comprises a detectable label selected from the group consisting of 3 H and 125 I.

Assignments (4)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 25, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023837/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2007
From: GARCIA-CALVO, MARIA MARGARITA
To: MERCK & CO.
Reel/Frame 019509/0474 →